Glannaventa, Inc., is an early-stage medical device company structured around development of an outpatient / point-of-care endoscopic screening test for a silent killer of women :ovarian cancer. As individuals and as a team, the principals at Glannaventa have experience in development of lasers, optics, biophotonics, and image-guided surgery -- including realizing the first real-time, OCT-guided therapeutic surgical procedure in humans and the development of a revolutionary new treatment for cutaneous vascular lesions